Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 71, 209–249 (2021).
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 68, 394–424 (2018).
Messinger, Y. H. et al. Bortezomib combined with VXLD chemotherapy is highly effective in advanced B-lineage acute lymphoblastic leukemia allowing early study termination due to efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study. Blood 118, 251 (2011).
Hosomi, Y. et al. Gefitinib alone versus gefitinib plus chemotherapy for non–small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 Study. J. Clin. Oncol. 38, 115–123 (2020).
Baghban, R. et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 18, 59 (2020).
Alfarouk, K. O. et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 15, 1–13 (2015).
Gupta, P. K. Drug targeting in cancer chemotherapy: a clinical perspective. J. Pharm. Sci. 79, 949–962 (1990).
Tenchov, R., Bird, R., Curtze, A. E. & Zhou, Q. Lipid nanoparticles─from liposomes to mrna vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15, 16982–17015 (2021).
Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101–124 (2021).
Liu, J., Liu, Z., Pang, Y. & Zhou, H. The interaction between nanoparticles and immune system: application in the treatment of inflammatory diseases. J. Nanobiotechnol. 20, 127 (2022).
Herdiana, Y., Wathoni, N., Shamsuddin, S. & Muchtaridi, M. Drug release study of the chitosan-based nanoparticles. Heliyon 8, e08674 (2022).
Senapati, S., Mahanta, A. K., Kumar, S. & Maiti, P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct. Target. Ther. 3, 7 (2018).
Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751–760 (2007).
Joy, R., George, J. & John, F. Brief outlook on polymeric nanoparticles, micelles, niosomes, hydrogels and liposomes: preparative methods and action. ChemistrySelect 7, e202104045 (2022).
Cabral, H., Miyata, K., Osada, K. & Kataoka, K. Block copolymer micelles in nanomedicine applications. Chem. Rev. 118, 6844–6892 (2018).
He, M. et al. Delivery of triptolide with reduction-sensitive polymer nanoparticles for liver cancer therapy on patient-derived xenografts models. Chin. Chem. Lett. 31, 3178–3182 (2020).
Hong, Z. et al. Local delivery of superagonist gene based on polymer nanoparticles for cancer immunotherapy. Chin. Chem. Lett. 34, 107603 (2023).
Kamaly, N., Yameen, B., Wu, J. & Farokhzad, O. C. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem. Rev. 116, 2602–2663 (2016).
Dahmana, N. et al. Ocular biodistribution of spironolactone after a single intravitreal injection of a biodegradable sustained-release polymer in rats. Mol. Pharm. 17, 59–69 (2020).
Wang, X., Cheng, R., Cheng, L. & Zhong, Z. Lipoyl ester terminated star PLGA as a simple and smart material for controlled drug delivery application. Biomacromolecules 19, 1368–1373 (2018).
Ferreira Soares, D. C., Domingues, S. C., Viana, D. B. & Tebaldi, M. L. Polymer-hybrid nanoparticles: current advances in biomedical applications. Biomed. Pharmacother. 131, 110695 (2020).
Hajba, L. & Guttman, A. The use of magnetic nanoparticles in cancer theranostics: toward handheld diagnostic devices. Biotechnol. Adv. 34, 354–361 (2016).
He, C., Lu, J. & Lin, W. Hybrid nanoparticles for combination therapy of cancer. J. Control. Rel. 219, 224–236 (2015).
Pelegri-O’Day, E. M., Lin, E.-W. & Maynard, H. D. Therapeutic protein–polymer conjugates: advancing beyond PEGylation. J. Am. Chem. Soc. 136, 14323–14332 (2014).
Singh, A. P., Biswas, A., Shukla, A. & Maiti, P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct. Target. Ther. 4, 33 (2019).
Mhlwatika, Z. & Aderibigbe, B. A. Application of dendrimers for the treatment of infectious diseases. Molecules 23, 2205 (2018).
García-Gallego, S. et al. Function oriented molecular design: dendrimers as novel antimicrobials. Molecules 22, 1581 (2017).
Santos, A., Veiga, F. & Figueiras, A. Dendrimers as pharmaceutical excipients: synthesis, properties, toxicity and biomedical applications. Materials 13, 65 (2019).
Tomalia, D. A., Nixon, L. S. & Hedstrand, D. M. The role of branch cell symmetry and other critical nanoscale design parameters in the determination of dendrimer encapsulation properties. Biomolecules 10, 642 (2020).
Recio-Ruiz, J. et al. Amphiphilic dendritic hydrogels with carbosilane nanodomains: preparation and characterization as drug delivery systems. Chem. Mater. 35, 2797–2807 (2023).
Srinageshwar, B. et al. PAMAM dendrimers cross the blood–brain barrier when administered through the carotid artery in C57BL/6J mice. Int. J. Mol. Sci. 18, 628 (2017).
Vacas-Cordoba, E. et al. Antiviral mechanism of polyanionic carbosilane dendrimers against HIV-1. Int. J. Nanomed. 11, 1281 (2016).
Kaminskas, L. M. et al. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. J. Control. Rel. 152, 241–248 (2011).
Ambekar, R. S., Choudhary, M. & Kandasubramanian, B. Recent advances in dendrimer-based nanoplatform for cancer treatment: a review. Eur. Polym. J. 126, 109546 (2020).
Owen, S. C., Chan, D. P. Y. & Shoichet, M. S. Polymeric micelle stability. Nano Today 7, 53–65 (2012).
O’Brien, F. J. Biomaterials & scaffolds for tissue engineering. Mater. Today 14, 88–95 (2011).
Hussein, Y. H. A. & Youssry, M. Polymeric micelles of biodegradable diblock copolymers: enhanced encapsulation of hydrophobic drugs. Materials 11, 688 (2018).
Cong, Z. et al. Multispectral optoacoustic tomography (MSOT) for imaging the particle size-dependent intratumoral distribution of polymeric micelles. Int. J. Nanomed. 13, 8549 (2018).
Zhang, N., Wang, Z. & Zhao, Y. Selective inhibition of Tumor necrosis factor receptor-1 (TNFR1) for the treatment of autoimmune diseases. Cytokine Growth Factor Rev. 55, 80–85 (2020).
Yang, Z. et al. Thermo-and pH-dual responsive polymeric micelles with upper critical solution temperature behavior for photoacoustic imaging-guided synergistic chemo-photothermal therapy against subcutaneous and metastatic breast tumors. Theranostics 8, 4097–4115 (2018).
Gao, W., Ye, G., Duan, X., Yang, X. & Yang, V. C. Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer. Int. J. Nanomed. 12, 1047 (2017).
Li, X. et al. A folate modified pH sensitive targeted polymeric micelle alleviated systemic toxicity of doxorubicin (DOX) in multi-drug resistant tumor bearing mice. Eur. J. Pharm. Sci. 76, 95–101 (2015).
Shan, H., Yin, W., Wen, L., Mao, A. & Lang, M. An injectable thermo-sensitive hydrogel of PNICL-PEG-PNICL block copolymer as a sustained release carrier of EGCG. Eur. Polym. J. 195, 112214 (2023).
Li, M. et al. Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery. Drug Deliv. 26, 481–489 (2019).
Hou, Y. et al. Ultra-small micelles based on polyoxyl 15 hydroxystearate for ocular delivery of myricetin: optimization, in vitro, and in vivo evaluation. Drug Deliv. 26, 158–167 (2019).
Akbarzadeh, A. et al. Liposome: classification, preparation, and applications. Nanoscale Res. Lett. 8, 102 (2013).
Huang, Z. et al. Progress involving new techniques for liposome preparation. Asian J. Pharm. Sci. 9, 176–182 (2014).
Otake, K. et al. Preparation of liposomes using an improved supercritical reverse phase evaporation method. Langmuir 22, 2543–2550 (2006).
Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36–48 (2013).
Jin, Y., Liang, X., An, Y. & Dai, Z. Microwave-triggered smart drug release from liposomes co-encapsulating doxorubicin and salt for local combined hyperthermia and chemotherapy of cancer. Bioconjug. Chem. 27, 2931–2942 (2016).
Xiao, Q. et al. Liposome-based anchoring and core-encapsulation for combinatorial cancer therapy. Chin. Chem. Lett. 33, 4191–4196 (2022).
Petersen, A. L., Hansen, A. E., Gabizon, A. & Andresen, T. L. Liposome imaging agents in personalized medicine. Adv. Drug Deliv. Rev. 64, 1417–1435 (2012).
Børresen, B. et al. Theranostic imaging may vaccinate against the therapeutic benefit of long circulating PEGylated liposomes and change cargo pharmacokinetics. ACS Nano 12, 11386–11398 (2018).
Zununi Vahed, S., Salehi, R., Davaran, S. & Sharifi, S. Liposome-based drug co-delivery systems in cancer cells. Mater. Sci. Eng. C. 71, 1327–1341 (2017).
Zhang, D. et al. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat. Nanotechnol. 17, 777–787 (2022).
Sun, L. et al. Additive nanomanufacturing of lab-on-a-chip fluorescent peptide nanoparticle arrays for Alzheimer’s disease diagnosis. Bio-Des. Manuf. 1, 182–194 (2018).
Sun, L. et al. Fluorescent peptide nanoparticles to detect amyloid-beta aggregation in cerebrospinal fluid and serum for Alzheimer’s disease diagnosis and progression monitoring. Chem. Eng. J. 405, 126733 (2021).
Liu, D., Fu, D., Zhang, L. & Sun, L. Detection of amyloid-beta by Fmoc-KLVFF self-assembled fluorescent nanoparticles for Alzheimer’s disease diagnosis. Chin. Chem. Lett. 32, 1066–1070 (2021).
Sun, L., Lei, Y., Wang, Y. & Liu, D. Blood-based Alzheimer’s disease diagnosis using fluorescent peptide nanoparticle arrays. Chin. Chem. Lett. 33, 1946–1950 (2022).
Fan, Z., Sun, L., Huang, Y., Wang, Y. & Zhang, M. Bioinspired fluorescent dipeptide nanoparticles for targeted cancer cell imaging and real-time monitoring of drug release. Nat. Nanotechnol. 11, 388–394 (2016).
Sun, M., Hu, H., Sun, L. & Fan, Z. The application of biomacromolecules to improve oral absorption by enhanced intestinal permeability: a mini-review. Chin. Chem. Lett. 31, 1729–1736 (2020).
Iglesias, J. nab-Paclitaxel (Abraxane®): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors. Breast Cancer Res. 11, S21 (2009).
Hawkins, M. J., Soon-Shiong, P. & Desai, N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 60, 876–885 (2008).
Zhen, X., Cheng, P. & Pu, K. Recent advances in cell membrane–camouflaged nanoparticles for cancer phototherapy. Small 15, 1804105 (2019).
Fang, R. H., Kroll, A. V., Gao, W. & Zhang, L. Cell membrane coating nanotechnology. Adv. Mater. 30, 1706759 (2018).
Hu, C.-M. J. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980–10985 (2011).
Wei, X. et al. Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia. Biomaterials 111, 116–123 (2016).
Li, R., He, Y., Zhang, S., Qin, J. & Wang, J. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharm. Sin. B. 8, 14–22 (2018).
Hu, Q. et al. Anticancer platelet-mimicking nanovehicles. Adv. Mater. 27, 7043–7050 (2015).
Brühwiler, D. Postsynthetic functionalization of mesoporous silica. Nanoscale 2, 887–892 (2010).
Tang, F., Li, L. & Chen, D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv. Mater. 24, 1504–1534 (2012).
Popat, A., Liu, J., Lu, G. Q. & Qiao, S. Z. A pH-responsive drug delivery system based on chitosan coated mesoporous silica nanoparticles. J. Mater. Chem. 22, 11173–11178 (2012).
He, Q. et al. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses. Biomaterials 31, 1085–1092 (2010).
Liu, X. et al. Enzyme-powered hollow nanorobots for active microsampling enabled by thermoresponsive polymer gating. ACS Nano 16, 10354–10363 (2022).
Yanes, R. E. & Tamanoi, F. Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Ther. Deliv. 3, 389–404 (2012).
Cai, Y., Deng, T., Pan, Y. & Zink, J. I. Use of ferritin capped mesoporous silica nanoparticles for redox and pH triggered drug release in vitro and in vivo. Adv. Funct. Mater. 30, 2002043 (2020).
Yang, S. et al. Tumor-targeted biodegradable multifunctional nanoparticles for cancer theranostics. Chem. Eng. J. 378, 122171 (2019).
Wang, Y. et al. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomed. Nanotechnol. Biol. Med. 11, 313–327 (2015).
Yang, S., Zhou, L., Su, Y., Zhang, R. & Dong, C.-M. One-pot photoreduction to prepare NIR-absorbing plasmonic gold nanoparticles tethered by amphiphilic polypeptide copolymer for synergistic photothermal-chemotherapy. Chin. Chem. Lett. 30, 187–191 (2019).
Singh, P. et al. Gold nanoparticles in diagnostics and therapeutics for human cancer. Int. J. Mol. Sci. 19, 1979 (2018).
Singh, P. et al. In vitro anti-inflammatory activity of spherical silver nanoparticles and monodisperse hexagonal gold nanoparticles by fruit extract of Prunus serrulata: a green synthetic approach. Artif. Cells Nanomed. Biotechnol. 46, 2022–2032 (2018).
Singh, P. et al. Biogenic silver and gold nanoparticles synthesized using red ginseng root extract, and their applications. Artif. Cells Nanomed. Biotechnol. 44, 811–816 (2016).
Aldewachi, H. et al. Gold nanoparticle-based colorimetric biosensors. Nanoscale 10, 18–33 (2017).
Singh, P. et al. Extracellular synthesis of silver and gold nanoparticles by Sporosarcina koreensis DC4 and their biological applications. Enzym. Microb. Technol. 86, 75–83 (2016).
Menon, J. U. et al. Nanomaterials for photo-based diagnostic and therapeutic applications. Theranostics 3, 152–166 (2013).
Ali, M. R. et al. Efficacy, long-term toxicity, and mechanistic studies of gold nanorods photothermal therapy of cancer in xenograft mice. Proc. Natl Acad. Sci. USA 114, E3110–E3118 (2017).
Chang, X. et al. Multifunctional Au modified Ti3C2-MXene for photothermal/enzyme dynamic/immune synergistic therapy. Nano Lett. 22, 8321–8330 (2022).
Kumar, D., Saini, N., Jain, N., Sareen, R. & Pandit, V. Gold nanoparticles: an era in bionanotechnology. Expert Opin. Drug Deliv. 10, 397–409 (2013).
Liu, T. et al. Tumor-specific photothermal-therapy-assisted immunomodulation via multiresponsive adjuvant nanoparticles. Adv. Mater. 35, 2300086 (2023).
Gasparri, A. M. et al. Boosting interleukin-12 antitumor activity and synergism with immunotherapy by targeted delivery with isoDGR-tagged nanogold. Small 15, 1903462 (2019).
Kong, F.-Y. et al. Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications. Molecules 22, 1445 (2017).
Palanisamy, S. & Wang, Y.-M. Superparamagnetic iron oxide nanoparticulate system: synthesis, targeting, drug delivery and therapy in cancer. Dalton Trans. 48, 9490–9515 (2019).
Cano, M., Núñez-Lozano, R., Dumont, Y., Larpent, C. & de la Cueva-Méndez, G. Synthesis and characterization of multifunctional superparamagnetic iron oxide nanoparticles (SPION)/C 60 nanocomposites assembled by fullerene–amine click chemistry. RSC Adv. 6, 70374–70382 (2016).
Dadfar, S. M. et al. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv. Drug Deliv. Rev. 138, 302–325 (2019).
Zhao, Z. et al. Recent advances in engineering iron oxide nanoparticles for effective magnetic resonance imaging. Bioact. Mater. 12, 214–245 (2022).
Santhosh, P. B. & Ulrih, N. P. Multifunctional superparamagnetic iron oxide nanoparticles: promising tools in cancer theranostics. Cancer Lett. 336, 8–17 (2013).
Zrazhevskiy, P., Sena, M. & Gao, X. Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem. Soc. Rev. 39, 4326–4354 (2010).
Yan, X. et al. Highly green fluorescent Nb2C MXene quantum dots for Cu2+ ion sensing and cell imaging. Chin. Chem. Lett. 31, 3173–3177 (2020).
Bajwa, N., Mehra, N. K., Jain, K. & Jain, N. K. Pharmaceutical and biomedical applications of quantum dots. Artif. Cells Nanomed. Biotechnol. 44, 758–768 (2016).
Qi, L. & Gao, X. Emerging application of quantum dots for drug delivery and therapy. Expert Opin. Drug Deliv. 5, 263–267 (2008).
Bertino, M. F. et al. Quantum dots by ultraviolet and x-ray lithography. Nanotechnology 18, 315603 (2007).
Valizadeh, A. et al. Quantum dots: synthesis, bioapplications, and toxicity. Nanoscale Res. Lett. 7, 480 (2012).
Sun, S. et al. Highly luminescence manganese doped carbon dots. Chin. Chem. Lett. 30, 1051–1054 (2019).
Iannazzo, D. et al. Graphene quantum dots for cancer targeted drug delivery. Int. J. Pharm. 518, 185–192 (2017).
Li, Y. et al. Bright, magnetic NIR-II quantum dot probe for sensitive dual-modality imaging and intensive combination therapy of cancer. ACS Nano 16, 8076–8094 (2022).
Krätschmer, W., Lamb, L. D., Fostiropoulos, K. & Huffman, D. R. Solid C60: a new form of carbon. Nature 347, 354–358 (1990).
Liu, Z., Robinson, J. T., Tabakman, S. M., Yang, K. & Dai, H. Carbon materials for drug delivery & cancer therapy. Mater. Today 14, 316–323 (2011).
Cantoro, M. et al. Catalytic chemical vapor deposition of single-wall carbon nanotubes at low temperatures. Nano Lett. 6, 1107–1112 (2006).
Eatemadi, A. et al. Carbon nanotubes: properties, synthesis, purification, and medical applications. Nanoscale Res. Lett. 9, 393 (2014).
Li, Z., de Barros, A. L. B., Soares, D. C. F., Moss, S. N. & Alisaraie, L. Functionalized single-walled carbon nanotubes: cellular uptake, biodistribution and applications in drug delivery. Int. J. Pharm. 524, 41–54 (2017).
Lay, C. L., Liu, J. & Liu, Y. Functionalized carbon nanotubes for anticancer drug delivery. Expert Rev. Med. Devices 8, 561–566 (2011).
Hadidi, N., Kobarfard, F., Nafissi-Varcheh, N. & Aboofazeli, R. PEGylated single-walled carbon nanotubes as nanocarriers for cyclosporin a delivery. AAPS PharmSciTech 14, 593–600 (2013).
Wang, J. T.-W. & Al-Jamal, K. T. Functionalized carbon nanotubes: revolution in brain delivery. Nanomedicine 10, 2639–2642 (2015).
Yang, R. et al. Single-walled carbon nanotubes-mediated in vivo and in vitro delivery of siRNA into antigen-presenting cells. Gene Ther. 13, 1714–1723 (2006).
Bao, X. et al. In vivo theranostics with near-infrared-emitting carbon dots—highly efficient photothermal therapy based on passive targeting after intravenous administration. Light Sci. Appl. 7, 91 (2018).
Chen, Z. et al. User-defined gestures for gestural interaction: extending from hands to other body parts. Int. J. Hum. Comput. Interact. 34, 238–250 (2018).
Bridgman, P. Two new modifications of phosphorus. J. Am. Chem. Soc. 36, 1344–1363 (1914).
Wu, F. et al. Black phosphorus nanosheets-based nanocarriers for enhancing chemotherapy drug sensitiveness via depleting mutant p53 and resistant cancer multimodal therapy. Chem. Eng. J. 370, 387–399 (2019).
Fojtů, M., Chia, X., Sofer, Z., Masařík, M. & Pumera, M. Black phosphorus nanoparticles potentiate the anticancer effect of oxaliplatin in ovarian cancer cell line. Adv. Funct. Mater. 27, 1701955 (2017).
Deng, L. et al. Functionalization of small black phosphorus nanoparticles for targeted imaging and photothermal therapy of cancer. Sci. Bull. 63, 917–924 (2018).
Sun, C. et al. One-pot solventless preparation of PEGylated black phosphorus nanoparticles for photoacoustic imaging and photothermal therapy of cancer. Biomaterials 91, 81–89 (2016).
Oliva González, C. M., Kharisov, B. I. & Kharissova, O. V. & Serrano Quezada, T.E. Synthesis and applications of MOF-derived nanohybrids: A review. Mater. Today. Proc. 46, 3018–3029 (2021).
Zhang, H. et al. MOF-derived nanohybrids for electrocatalysis and energy storage: current status and perspectives. Chem. commun. 54, 5268–5288 (2018).
Wuttke, S., Lismont, M., Escudero, A., Rungtaweevoranit, B. & Parak, W. J. Positioning metal-organic framework nanoparticles within the context of drug delivery–a comparison with mesoporous silica nanoparticles and dendrimers. Biomaterials 123, 172–183 (2017).
Liu, J., Huang, J., Zhang, L. & Lei, J. Multifunctional metal–organic framework heterostructures for enhanced cancer therapy. Chem. Soc. Rev. 50, 1188–1218 (2021).
Li, Y., Zhou, J., Wang, L. & Xie, Z. Endogenous hydrogen sulfide-triggered MOF-based nanoenzyme for synergic cancer therapy. ACS Appl. Mater. Interfaces 12, 30213–30220 (2020).
Zheng, D., Yang, K. & Nie, Z. Engineering heterogeneity of precision nanoparticles for biomedical delivery and therapy. VIEW 2, 20200067 (2021).
Kumar, R. et al. Core–shell nanostructures: perspectives towards drug delivery applications. J. Mater. Chem. B 8, 8992–9027 (2020).
Su, H. et al. Janus particles: design, preparation, and biomedical applications. Mater. Today Bio 4, 100033 (2019).
Shah, S., Famta, P., Raghuvanshi, R. S., Singh, S. B. & Srivastava, S. Lipid polymer hybrid nanocarriers: Insights into synthesis aspects, characterization, release mechanisms, surface functionalization and potential implications. Colloids Interface Sci. Commun. 46, 100570 (2022).
Zhao, Y. et al. Topologically induced heterogeneity in gradient copolymer brush particle materials. Macromolecules 55, 8846–8856 (2022).
Dai, X., Zhang, X., Gao, L., Xu, Z. & Yan, L.-T. Topology mediates transport of nanoparticles in macromolecular networks. Nat. Commun. 13, 4094 (2022).
Li, M., Zhao, G., Su, W.-K. & Shuai, Q. Enzyme-responsive nanoparticles for anti-tumor drug delivery. Front. Chem. 8, 647 (2020).
Wang, L. et al. Disentangling light- and temperature-induced thermal effects in colloidal Au nanoparticles. J. Phys. Chem. C. 126, 3591–3599 (2022).
Kawamura, A., Katoh, T., Uragami, T. & Miyata, T. Design of molecule-responsive organic–inorganic hybrid nanoparticles bearing cyclodextrin as ligands. Polym. J. 47, 206–211 (2015).
Hossen, S. et al. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J. Adv. Res. 15, 1–18 (2019).
Liao, J. et al. Physical‐, chemical‐, and biological‐responsive nanomedicine for cancer therapy. Wiley Interdiscip. Rev. Nanomed. 12, e1581 (2020).
Kanamala, M., Wilson, W. R., Yang, M., Palmer, B. D. & Wu, Z. J. B. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials 85, 152–167 (2016).
Liu, J. et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol. Adv. 32, 693–710 (2014).
Qiao, Y. et al. Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy. Wiley Interdiscip. Rev. Nanomed. 11, e1527 (2019).
Li, R., Peng, F., Cai, J., Yang, D. & Zhang, P. Redox dual-stimuli responsive drug delivery systems for improving tumor-targeting ability and reducing adverse side effects. Asian J. Pharm. Sci. 15, 311–325 (2020).
Zhang, Z.-T., Huang-Fu, M.-Y., Xu, W.-H. & Han, M. Stimulus-responsive nanoscale delivery systems triggered by the enzymes in the tumor microenvironment. Eur. J. Pharm. Biopharm. 137, 122–130 (2019).
De La Rica, R., Aili, D. & Stevens, M. M. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv. Drug Deliv. Rev. 64, 967–978 (2012).
Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161–174 (2002).
Tauro, M., McGuire, J. & Lynch, C. C. New approaches to selectively target cancer-associated matrix metalloproteinase activity. Cancer Metastasis Rev. 33, 1043–1057 (2014).
Turk, V. et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta Proteins Proteom. 1824, 68–88 (2012).
Mijanović, O. et al. Cathepsin B: a sellsword of cancer progression. Cancer Lett. 449, 207–214 (2019).
Maciewicz, R. A., Wotton, S. F., Etherington, D. J. & Duance, V. C. Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS Lett. 269, 189–193 (1990).
Sevenich, L. et al. Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. Oncogene 30, 54–64 (2011).
Dheer, D., Nicolas, J. & Shankar, R. Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases. Adv. Drug Deliv. Rev. 151-152, 130–151 (2019).
Mahmood, N., Mihalcioiu, C. & Rabbani, S. A. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front. Oncol. 8, 24 (2018).
Noh, H., Hong, S. & Huang, S. Role of urokinase receptor in tumor progression and development. Theranostics 3, 487–495 (2013).
Alpízar-Alpízar, W. et al. Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries. Int. J. Cancer 126, 405–415 (2010).
Su, S.-C., Lin, C.-W., Yang, W.-E., Fan, W.-L. & Yang, S.-F. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin. Ther. Targets 20, 551–566 (2016).
Brglez, V., Lambeau, G. & Petan, T. Secreted phospholipases A2 in cancer: diverse mechanisms of action. Biochimie 107, 114–123 (2014).
Brglez, V., Pucer, A., Pungerčar, J., Lambeau, G. & Petan, T. Secreted phospholipases A2 are differentially expressed and epigenetically silenced in human breast cancer cells. Biochem. Biophys. Res. Commun. 445, 230–235 (2014).
Li, H. et al. Imaging γ-Glutamyltranspeptidase for tumor identification and resection guidance via enzyme-triggered fluorescent probe. Biomaterials 179, 1–14 (2018).
McAtee, C. O., Barycki, J. J. & Simpson, M. A. Chapter One – emerging roles for hyaluronidase in cancer metastasis and therapy. In: Advances in Cancer Research, 123 (eds. Simpson, M. A. & Heldin, P.) 1–34 (Academic Press, 2014).
Moradi, A., Srinivasan, S., Clements, J. & Batra, J. Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment. Cancer Metastasis Rev. 38, 333–346 (2019).
Hou, X.-F., Chen, Y. & Liu, Y. Enzyme-responsive protein/polysaccharide supramolecular nanoparticles. Soft Matter 11, 2488–2493 (2015).
Kim, E.-J. et al. In vivo imaging of β-galactosidase stimulated activity in hepatocellular carcinoma using ligand-targeted fluorescent probe. Biomaterials 122, 83–90 (2017).
Rao, J. & Khan, A. Enzyme sensitive synthetic polymer micelles based on the azobenzene motif. J. Am. Chem. Soc. 135, 14056–14059 (2013).
Mo, R. & Gu, Z. Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery. Mater. Today 19, 274–283 (2016).
Zhang, X. et al. Recent progress and advances in redox-responsive polymers as controlled delivery nanoplatforms. Mater. Chem. Front. 1, 807–822 (2017).
Guo, X. et al. Advances in redox-responsive drug delivery systems of tumor microenvironment. J. Nanobiotechnol. 16, 74 (2018).
Huo, M., Yuan, J., Tao, L. & Wei, Y. Redox-responsive polymers for drug delivery: from molecular design to applications. Polym. Chem. 5, 1519–1528 (2014).
Li, L. et al. Functional biomimetic nanoparticles for drug delivery and theranostic applications in cancer treatment. Sci. Technol. Adv. Mater. 19, 771–790 (2018).
Liu, M., Du, H., Zhang, W. & Zhai, G. Internal stimuli-responsive nanocarriers for drug delivery: design strategies and applications. Mater. Sci. Eng. C. 71, 1267–1280 (2017).
Liu, D., Yang, F., Xiong, F. & Gu, N. The smart drug delivery system and its clinical potential. Theranostics 6, 1306–1323 (2016).
Kim, Y.-J. & Matsunaga, Y. T. Thermo-responsive polymers and their application as smart biomaterials. J. Mater. Chem. B 5, 4307–4321 (2017).
Guo, X. et al. Thermo-triggered drug release from actively targeting polymer micelles. ACS Appl. Mater. Interfaces 6, 8549–8559 (2014).
Kim, Y. J. & Matsunaga, Y. T. Thermo-responsive polymers and their application as smart biomaterials. J. Mater. Chem. B 5, 4307–4321 (2017).
Tian, H., Tang, Z., Zhuang, X., Chen, X. & Jing, X. Biodegradable synthetic polymers: Preparation, functionalization and biomedical application. Progr. Poly. Sci. 37, 237–280 (2012).
Hou, W. et al. Photo-Responsive polymersomes as drug delivery system for potential medical applications. Molecules 25, 5147 (2020).
Li, C. et al. Recent progress in drug delivery. Acta Pharm. Sin. B. 9, 1145–1162 (2019).
Zhang, L., Qian, M. & Wang, J. Progress in research of photo-controlled drug delivery systems. Acta Chim. Sin. 75, 770–782 (2017).
Zhou, L.-Q., Li, P., Cui, X.-W. & Dietrich, C. F. Ultrasound nanotheranostics in fighting cancer: advances and prospects. Cancer Lett. 470, 204–219 (2020).
Pham, S. H., Choi, Y. & Choi, J. Stimuli-responsive nanomaterials for application in antitumor therapy and drug delivery. Pharmaceutics 12, 630 (2020).
Greish, K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Cancer Nanotechnol. 624, 25–37 (2010).
Chandan, R., Mehta, S. & Banerjee, R. Ultrasound-responsive carriers for therapeutic applications. ACS Biomater. Sci. Eng. 6, 4731–4747 (2020).
Aguilar, A. A. et al. Permeabilizing cell membranes with electric fields. Cancers 13, 2283 (2021).
George, P. M. et al. Electrically controlled drug delivery from biotin‐doped conductive polypyrrole. Adv. Mater. 18, 577–581 (2006).
Liu, S. et al. Conjugated polymer for voltage‐controlled release of molecules. Adv. Mater. 29, 1701733 (2017).
Yue, R. & Xu, J. Poly (3, 4-ethylenedioxythiophene) as promising organic thermoelectric materials: a mini-review. Synth. Met. 162, 912–917 (2012).
Yang, H. Y., Li, Y. & Lee, D. S. Multifunctional and stimuli-responsive magnetic nanoparticle-based delivery systems for biomedical applications. Adv. Ther. 1, 1800011 (2018).
Kobayashi, T. Cancer hyperthermia using magnetic nanoparticles. Biotechnol. J. 6, 1342–1347 (2011).
Li, S. et al. Targeted inhibition of tumor inflammation and tumor-platelet crosstalk by nanoparticle-mediated drug delivery mitigates cancer metastasis. ACS Nano 16, 50–67 (2022).
Yu, Y. et al. A tumor-specific MicroRNA recognition system facilitates the accurate targeting to tumor cells by magnetic nanoparticles. Mol. Ther. Nucleic Acids 5, e318 (2016).
Semkina, A. S. et al. Magnetic resonance imaging of tumors with the use of iron oxide magnetic nanoparticles as a contrast agent. Bull. Exp. Biol. Med. 162, 808–811 (2017).
Tietze, R. et al. Magnetic nanoparticle-based drug delivery for cancer therapy. Biochem. Biophys. Res. Commun. 468, 463–470 (2015).
Estelrich, J., Escribano, E., Queralt, J. & Busquets, M. Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery. Int. J. Mol. Sci. 16, 8070–8101 (2015).
Mertz, D., Sandre, O. & Begin-Colin, S. Drug releasing nanoplatforms activated by alternating magnetic fields. Biochim. Biophys. Acta Gen. Subj. 1861, 1617–1641 (2017).
Maeda, H., Nakamura, H. & Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65, 71–79 (2013).
Maeda, H. The 35th Anniversary of the Discovery of EPR effect: a new wave of nanomedicines for tumor-targeted drug delivery—personal remarks and future prospects. J. Pers. Med. 11, 229 (2021).
McDaid, W. J. et al. Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours. Nanoscale 11, 20261–20273 (2019).
Chen, R. et al. Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment. Biomater. Sci. 9, 2279–2294 (2021).
Hirata, Y. et al. A simple, fast, and orientation-controllable technology for preparing antibody-modified liposomes. Int. J. Pharm. 607, 120966 (2021).
Grinberg, O., Gedanken, A., Mukhopadhyay, D. & Patra, C. R. Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine. Polym. Adv. Technol. 24, 294–299 (2013).
Zheng, M. et al. Poly(α-l-lysine)-based nanomaterials for versatile biomedical applications: Current advances and perspectives. Bioact. Mater. 6, 1878–1909 (2021).
Liu, D., Liu, F., Liu, Z., Wang, L. & Zhang, N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol. Pharm. 8, 2291–2301 (2011).
Chen, H. et al. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J. Control. Rel. 128, 209–216 (2008).
Niza, E. et al. Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of dasatinib in HER2+ metastasic breast cancer. Nanomaterials 9, 1793 (2019).
Fu, Q., Wang, J. & Liu, H. Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles. Drug Deliv. 27, 1535–1543 (2020).
Wu, L. et al. Discovery of pemigatinib: a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. J. Med. Chem. 64, 10666–10679 (2021).
Xiao, J.-F., Caliri, A. W., Duex, J. E. & Theodorescu, D. Targetable pathways in advanced bladder cancer: FGFR signaling. Cancers 13, 4891 (2021).
Hortelão, A. C., Carrascosa, R., Murillo-Cremaes, N., Patiño, T. & Sánchez, S. Targeting 3D bladder cancer spheroids with urease-powered nanomotors. ACS Nano 13, 429–439 (2019).
Ma, X. et al. P-glycoprotein antibody decorated porous hydrogel particles for capture and release of drug-resistant tumor cells. Adv. Healthc. Mater. 8, 1900136 (2019).
Cho, H.-S. et al. Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. ACS Nano 4, 5398–5404 (2010).
Vail, M. E. et al. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res. 74, 4470–4481 (2014).
Chu, L. et al. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Deliv. 25, 1634–1641 (2018).
Guo, M., Zhang, H., Zheng, J. & Liu, Y. Glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma. J. Cancer 11, 2008–2021 (2020).
Tang, X. et al. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Deliv. 25, 1484–1494 (2018).
Li, Y. et al. Antibody-modified reduced graphene oxide films with extreme sensitivity to circulating tumor cells. Adv. Mater. 27, 6848–6854 (2015).
Liu, D. et al. Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined hyperthermia and chemotherapy. Theranostics 10, 1181–1196 (2020).
Hama, S., Sakai, M., Itakura, S., Majima, E. & Kogure, K. Rapid modification of antibodies on the surface of liposomes composed of high-affinity protein A-conjugated phospholipid for selective drug delivery. Biochem. Biophys. Rep. 27, 101067 (2021).
Guo, Z. et al. CD47-targeted bismuth selenide nanoparticles actualize improved photothermal therapy by increasing macrophage phagocytosis of cancer cells. Colloids Surf. B 184, 110546 (2019).
Zhao, N., Qin, Y., Liu, H. & Cheng, Z. Tumor-targeting peptides: ligands for molecular imaging and therapy. Anti Cancer Agents Med. Chem. 18, 74–86 (2018).
Gao, H. et al. In situ formation of nanotheranostics to overcome the blood–brain barrier and enhance treatment of orthotopic glioma. ACS Appl. Mater. Interfaces 12, 26880–26892 (2020).
Liang, G., Jin, X., Zhang, S. & Xing, D. RGD peptide-modified fluorescent gold nanoclusters as highly efficient tumor-targeted radiotherapy sensitizers. Biomaterials 144, 95–104 (2017).
Negishi, Y. et al. Development of a screening system for targeting carriers using peptide-modified liposomes and tissue sections. Biol. Pharm. Bull. 41, 1107–1111 (2018).
Liu, Y. et al. Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma RNAi therapy. Nano Lett. 20, 1637–1646 (2020).
Zhang, N.-n et al. Gadolinium-loaded calcium phosphate nanoparticles for magnetic resonance imaging of orthotopic hepatocarcinoma and primary hepatocellular carcinoma. Biomater. Sci. 8, 1961–1972 (2020).
Du, Y.-Z. et al. Tumor cells-specific targeting delivery achieved by A54 peptide functionalized polymeric micelles. Biomaterials 33, 8858–8867 (2012).
Chernenko, T. et al. Label-free Raman microspectral analysis for comparison of cellular uptake and distribution between nontargeted and EGFR-targeted biodegradable polymeric nanoparticles. Drug Deliv. Transl. Res. 3, 575–586 (2013).
Chen, Q. et al. Decoration of pH-sensitive copolymer micelles with tumor-specific peptide for enhanced cellular uptake of doxorubicin. Int. J. Nanomed. 11, 5415–5427 (2016).
Wang, Y. et al. Tumor cell targeted delivery by specific peptide-modified mesoporous silica nanoparticles. J. Mater. Chem. 22, 14608–14616 (2012).
Zhang, S. et al. A pH-sensitive T7 peptide-decorated liposome system for HER2 inhibitor extracellular delivery: an application for the efficient suppression of HER2+ breast cancer. J. Mater. Chem. B 9, 8768–8778 (2021).
Gao, L.-Y. et al. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. Biomaterials 35, 2066–2078 (2014).
Wang, Y. et al. Specific cell targeting with APRPG conjugated PEG–PLGA nanoparticles for treating ovarian cancer. Biomaterials 35, 983–992 (2014).
Yan, L. et al. Cell-penetrating peptide-modified PLGA nanoparticles for enhanced nose-to-brain macromolecular delivery. Macromol. Res. 21, 435–441 (2013).
Kanazawa, T., Taki, H., Tanaka, K., Takashima, Y. & Okada, H. Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm. Res. 28, 2130–2139 (2011).
Zou, L. et al. Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin. Biomaterials 182, 1–12 (2018).
Singh, T. et al. Intracellular delivery of oxaliplatin conjugate via cell penetrating peptide for the treatment of colorectal carcinoma in vitro and in vivo. Int. J. Pharm. 606, 120904 (2021).
Smith, J. D. et al. Therapeutic peptide delivery via aptamer-displaying, disulfide-linked peptide amphiphile micelles. Mol. Syst. Des. Eng. 5, 269–283 (2020).
Zhou, Z., Yan, Y., Wang, L., Zhang, Q. & Cheng, Y. Melanin-like nanoparticles decorated with an autophagy-inducing peptide for efficient targeted photothermal therapy. Biomaterials 203, 63–72 (2019).
Yang, C., Uertz, J., Yohan, D. & Chithrani, B. D. Peptide modified gold nanoparticles for improved cellular uptake, nuclear transport, and intracellular retention. Nanoscale 6, 12026–12033 (2014).
Mercier, M.-C., Dontenwill, M. & Choulier, L. Selection of nucleic acid aptamers targeting tumor cell-surface protein biomarkers. Cancers 9, 69 (2017).
Ellington, A. D. & Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818–822 (1990).
Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505–510 (1990).
Cruz-Toledo, J. et al. Aptamer base: a collaborative knowledge base to describe aptamers and SELEX experiments. Database 2012, bas006 (2012).
Wang, J. & Li, G. Aptamers against cell surface receptors: selection, modification and application. Curr. Med. Chem. 18, 4107–4116 (2011).
Lao, Y.-H., Phua, K. K. L. & Leong, K. W. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano 9, 2235–2254 (2015).
Lupold, S. E., Hicke, B. J., Lin, Y. & Coffey, D. S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen1. Cancer Res 62, 4029–4033 (2002).
Wu, X. et al. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int. J. Nanomed. 6, 1747–1756 (2011).
Baek, S. E. et al. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. J. Control. Release 196, 234–242 (2014).
Rockey, W. M. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther. 21, 299–314 (2011).
Zitzmann, S. et al. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin. Cancer Res. 11, 139–146 (2005).
Jo, H., Youn, H., Lee, S. & Ban, C. Ultra-effective photothermal therapy for prostate cancer cells using dual aptamer-modified gold nanostars. J. Mater. Chem. B 2, 4862–4867 (2014).
Jing, P. et al. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system. Cancer Lett. 383, 230–242 (2016).
Apostolopoulos, V., Stojanovska, L. & Gargosky, S. E. MUC1 (CD227): a multi-tasked molecule. Cell. Mol. Life Sci. 72, 4475–4500 (2015).
Heublein, S. et al. Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients. J. Exp. Clin. Cancer Res. 34, 50 (2015).
Han, X. et al. Multivalent aptamer-modified tetrahedral DNA nanocage demonstrates high selectivity and safety for anti-tumor therapy. Nanoscale 11, 339–347 (2019).
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D. & Trent, J. O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 86, 151–164 (2009).
Yazdian-Robati, R. et al. Therapeutic applications of AS1411 aptamer, an update review. Int. J. Biol. Macromol. 155, 1420–1431 (2020).
He, X. et al. Simple and efficient targeted intracellular protein delivery with self-assembled nanovehicles for effective cancer therapy. Adv. Funct. Mater. 29, 1906187 (2019).
Liang, X. et al. Nucleolin-targeting AS1411 aptamer-modified micelle for the co-delivery of doxorubicin and miR-519c to improve the therapeutic efficacy in hepatocellular carcinoma treatment. Int. J. Nanomed. 16, 2569–2584 (2021).
Lv, T. et al. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer. Acta Biomater. 76, 257–274 (2018).
Li, F. et al. Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer. Biomaterials 145, 56–71 (2017).
Prebet, T. et al. The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. Blood 116, 2315–2323 (2010).
Fang, Z. et al. Sgc8 aptamer targeted glutathione-responsive nanoassemblies containing Ara-C prodrug for the treatment of acute lymphoblastic leukemia. Nanoscale 11, 23000–23012 (2019).
Heo, D., Ku, M., Kim, J.-H., Yang, J. & Suh, J.-S. Aptamer-modified magnetic nanosensitizer for in vivo MR imaging of HER2-expressing cancer. Nanoscale Res. Lett. 13, 288 (2018).
Ara, M. N. et al. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells. Biomaterials 35, 7110–7120 (2014).
Luiz, M. T. et al. In vitro evaluation of folate-modified PLGA nanoparticles containing paclitaxel for ovarian cancer therapy. Mater. Sci. Eng. C. 105, 110038 (2019).
Luiz, M. T. et al. Docetaxel-loaded folate-modified TPGS-transfersomes for glioblastoma multiforme treatment. Mater. Sci. Eng. C. 124, 112033 (2021).
Zhao, J. et al. Folic acid and poly(ethylene glycol) decorated paclitaxel nanocrystals exhibit enhanced stability and breast cancer-targeting capability. ACS Appl. Mater. Interfaces 13, 14577–14586 (2021).
Gupta, A., Kaur, C. D., Saraf, S. & Saraf, S. Targeting of herbal bioactives through folate receptors: a novel concept to enhance intracellular drug delivery in cancer therapy. J. Recept. Signal Transduct. 37, 314–323 (2017).
Cui, S. et al. In vivo targeted deep-tissue photodynamic therapy based on near-infrared light triggered upconversion nanoconstruct. ACS Nano 7, 676–688 (2013).
Tortorella, S. & Karagiannis, C. T. The significance of transferrin receptors in oncology: the development of functional nano-based drug delivery systems. Curr. Drug Deliv. 11, 427–443 (2014).
Koneru, T. et al. Transferrin: biology and use in receptor-targeted nanotherapy of gliomas. ACS Omega 6, 8727–8733 (2021).
Liu, D.-z et al. The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle. Nanomed. Nanotechnol. Biol. Med. 14, 991–1003 (2018).
Hou, L., Shan, X., Hao, L., Feng, Q. & Zhang, Z. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform. Acta Biomater. 54, 307–320 (2017).
Cheng, L.-C. et al. Targeting polymeric fluorescent nanodiamond-gold/silver multi-functional nanoparticles as a light-transforming hyperthermia reagent for cancer cells. Nanoscale 5, 3931–3940 (2013).
Zhao, S., Zhu, X., Cao, C., Sun, J. & Liu, J. Transferrin modified ruthenium nanoparticles with good biocompatibility for photothermal tumor therapy. J. Colloid Interface Sci. 511, 325–334 (2018).
Zhao, B. et al. A transferrin triggered pathway for highly targeted delivery of graphene-based nanodrugs to treat choroidal melanoma. Adv. Healthc. Mater. 7, 1800377 (2018).
Upadhyay, P. et al. Transferrin-decorated thymoquinone-loaded PEG-PLGA nanoparticles exhibit anticarcinogenic effect in non-small cell lung carcinoma via the modulation of miR-34a and miR-16. Biomater. Sci. 7, 4325–4344 (2019).
Vargason, A. M., Anselmo, A. C. & Mitragotri, S. The evolution of commercial drug delivery technologies. Nat. Biomed. Eng. 5, 951–967 (2021).
Schmidt, B. et al. A natural history of botanical therapeutics. Metabolism 57, S3–S9 (2008).
Singh, B. et al. Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer. Biomaterials 280, 121302 (2022).
Cohen, Z. R. et al. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 9, 1581–1591 (2015).
Lewis, A. L., McEntee, N., Holland, J. & Patel, A. Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery. Drug Deliv. Transl. Res. 12, 1–6 (2022).
Savjani, K. T., Gajjar, A. K. & Savjani, J. K. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012, 195727 (2012).
Kalepu, S. & Nekkanti, V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm. Sin. B. 5, 442–453 (2015).
Sharma, P. C., Jain, A., Jain, S., Pahwa, R. & Yar, M. S. Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. J. Enzym. Inhib. Med. Chem. 25, 577–589 (2010).
Li, G. et al. Small-molecule prodrug nanoassemblies: an emerging nanoplatform for anticancer drug delivery. Small 17, 2101460 (2021).
Zhang, Y., Cui, H., Zhang, R., Zhang, H. & Huang, W. Nanoparticulation of prodrug into medicines for cancer therapy. Adv. Sci. 8, 2101454 (2021).
Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 1, 10–29 (2016).
Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic: an update. Bioeng. Transl. Med. 4, e10143 (2019).
Shen, Y. et al. Multifunctioning pH-responsive nanoparticles from hierarchical self-assembly of polymer brush for cancer drug delivery. AIChE J. 54, 2979–2989 (2008).
Yin Win, K. & Feng, S.-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26, 2713–2722 (2005).
Champion, J. A., Walker, A. & Mitragotri, S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 25, 1815–1821 (2008).
Turecek, P. L., Bossard, M. J., Schoetens, F. & Ivens, I. A. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J. Pharm. Sci. 105, 460–475 (2016).
Barenholz, Y. Doxil® — the first FDA-approved nano-drug: Lessons learned. J. Control. Rel. 160, 117–134 (2012).
Rask-Andersen, M., Masuram, S. & Schiöth, H. B. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54, 9–26 (2014).
Lau, J. L. & Dunn, M. K. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg. Med. Chem. 26, 2700–2707 (2018).
Fu, D., Liu, D., Zhang, L. & Sun, L. Self-assembled fluorescent tripeptide nanoparticles for bioimaging and drug delivery applications. Chin. Chem. Lett. 31, 3195–3199 (2020).
Bruno, B. J., Miller, G. D. & Lim, C. S. Basics and recent advances in peptide and protein drug delivery. Ther. Deliv. 4, 1443–1467 (2013).
Craik, D. J., Fairlie, D. P., Liras, S. & Price, D. The future of peptide-based drugs. Chem. Biol. Drug Des. 81, 136–147 (2013).
Pisal, D. S., Kosloski, M. P. & Balu-Iyer, S. V. Delivery of therapeutic proteins. J. Pharm. Sci. 99, 2557–2575 (2010).
Schuster, J. et al. In vivo stability of therapeutic proteins. Pharm. Res. 37, 23 (2020).
Lin, W. et al. Self-assembly of an antitumor dipeptide induced near-infrared fluorescence and improved stability for theranostic applications. ACS Appl. Mater. Interfaces 13, 32799–32809 (2021).
Jevševar, S., Kunstelj, M. & Porekar, V. G. PEGylation of therapeutic proteins. Biotechnol. J. 5, 113–128 (2010).
Varela-Moreira, A. et al. Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model. Int. J. Pharm. 2, 100049 (2020).
Brown, T. D., Whitehead, K. A. & Mitragotri, S. Materials for oral delivery of proteins and peptides. Nat. Rev. Mater. 5, 127–148 (2020).
Drucker, D. J. Advances in oral peptide therapeutics. Nat. Rev. Drug Discov. 19, 277–289 (2020).
Morales, J. O. et al. Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes. AAPS J. 19, 652–668 (2017).
Moore, W. R. et al. Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model. J. Clin. Oncol. 39, 78–78 (2021).
Opalinska, J. B. & Gewirtz, A. M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503–514 (2002).
Rinaldi, C. & Wood, M. J. A. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9–21 (2018).
Van Hoecke, L. & Roose, K. How mRNA therapeutics are entering the monoclonal antibody field. J. Transl. Med. 17, 54 (2019).
Kaczmarek, J. C., Kowalski, P. S. & Anderson, D. G. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 9, 60 (2017).
Kormann, M. S. D. et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 29, 154–157 (2011).
Endoh, T. & Ohtsuki, T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev. 61, 704–709 (2009).
Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129–138 (2009).
Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14, 1084–1087 (2019).
Friend, D. S., Papahadjopoulos, D. & Debs, R. J. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim. Biophys. Acta Biomembr. 1278, 41–50 (1996).
Zelphati, O. & Szoka, F. C. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl Acad. Sci. USA 93, 11493–11498 (1996).
Lv, H., Zhang, S., Wang, B., Cui, S. & Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Rel. 114, 100–109 (2006).
Semple, S. C. et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta Biomembr. 1510, 152–166 (2001).
Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172–176 (2010).
Vargason, A. M. & Anselmo, A. C. Clinical translation of microbe-based therapies: current clinical landscape and preclinical outlook. Bioeng. Transl. Med. 3, 124–137 (2018).
Palucka, K. & Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 39, 38–48 (2013).
Frenette, P. S., Pinho, S., Lucas, D. & Scheiermann, C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu. Rev. Immunol. 31, 285–316 (2013).
Prasad, V. Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat. Rev. Clin. Oncol. 15, 11–12 (2018).
Jackson, H. J., Rafiq, S. & Brentjens, R. J. Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13, 370–383 (2016).
Cheever, M. A. & Higano, C. S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res 17, 3520–3526 (2011).
Riglar, D. T. & Silver, P. A. Engineering bacteria for diagnostic and therapeutic applications. Nat. Rev. Microbiol. 16, 214–225 (2018).
Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813–820 (2017).
Volkman, R. & Offen, D. Concise review: mesenchymal stem cells in neurodegenerative diseases. Stem Cells 35, 1867–1880 (2017).
Newick, K., O’Brien, S., Moon, E. & Albelda, S. M. CAR T cell therapy for solid tumors. Annu. Rev. Med. 68, 139–152 (2017).
Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563–571 (2018).
Zheng, C. et al. Engineering nano-therapeutics to boost adoptive cell therapy for cancer treatment. Small Methods 5, 2001191 (2021).
He, C., Tang, Z., Tian, H. & Chen, X. Co-delivery of chemotherapeutics and proteins for synergistic therapy. Adv. Drug Deliv. Rev. 98, 64–76 (2016).
Sun, L., Hu, Y. & Zhang, L. Recent trends in nanocrystals for pharmaceutical applications. Curr. Pharm. Des. 24, 2394–2402 (2018).
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y. & Wu, X. Y. Nanomedicine of synergistic drug combinations for cancer therapy – strategies and perspectives. J. Control. Rel. 240, 489–503 (2016).
Wang, H. & Huang, Y. Combination therapy based on nano codelivery for overcoming cancer drug resistance. Med. Drug Discov. 6, 100024 (2020).
Nastiuk, K. L. & Krolewski, J. J. Opportunities and challenges in combination gene cancer therapy. Adv. Drug Deliv. Rev. 98, 35–40 (2016).
Jaaks, P. et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 603, 166–173 (2022).
Tan, P., Chen, X., Zhang, H., Wei, Q. & Luo, K. Artificial intelligence aids in development of nanomedicines for cancer management. Semin. Cancer Biol. 89, 61–75 (2023).
Dahlman, J. E. et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc. Natl Acad. Sci. USA 114, 2060–2065 (2017).
Tahara, K. Pharmaceutical formulation and manufacturing using particle/powder technology for personalized medicines. Adv. Powder Technol. 31, 387–392 (2020).
Sheng, T. et al. Unmanned aerial vehicle mediated drug delivery for first aid. Adv. Mater. 35, 2208648 (2023).
Adir, O. et al. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv. Mater. 32, 1901989 (2020).
Zhu, M. et al. Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures. Nat. Nanotechnol. 18, 657–666 (2023).
Kim, M. et al. Detection of ovarian cancer via the spectral fingerprinting of quantum-defect-modified carbon nanotubes in serum by machine learning. Nat. Biomed. Eng. 6, 267–275 (2022).
Ando, K., Mori, K., Corradini, N., Redini, F. & Heymann, D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin. Pharmacother. 12, 285–292 (2011).
Dicko, A., Kwak, S., Frazier, A. A., Mayer, L. D. & Liboiron, B. D. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int. J. Pharm. 391, 248–259 (2010).
Brunetti, C., Anelli, L., Zagaria, A., Specchia, G. & Albano, F. CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds? Expert Rev. Hematol. 10, 853–862 (2017).
Chang, T. C. et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother. Pharmacol. 75, 579–586 (2015).
Cortes, J. E. et al. Phase II, multicenter, randomized trial of CPX‐351 (cytarabine: daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer 121, 234–242 (2015).
Huang, X. et al. Comparative study of photothermolysis of cancer cells with nuclear-targeted or cytoplasm-targeted gold nanospheres: continuous wave or pulsed lasers. J. Biomed. Opt. 15, 58002 (2010).
Chen, H. et al. DUP1 peptide modified micelle efficiently targeted delivery paclitaxel and enhance mitochondrial apoptosis on PSMA-negative prostate cancer cells. SpringerPlus 5, 362 (2016).
Mu, W. et al. Promoting early diagnosis and precise therapy of hepatocellular carcinoma by glypican-3-targeted synergistic chemo-photothermal theranostics. ACS Appl. Mater. Interfaces 11, 23591–23604 (2019).
Huang, N. et al. Efficacy of NGR peptide-modified PEGylated quantum dots for crossing the blood–brain barrier and targeted fluorescence imaging of glioma and tumor vasculature. Nanomed. Nanotechnol. Biol. Med. 13, 83–93 (2017).
Jang, H. J., Jeong, E. J. & Lee, K. Y. Carbon dioxide-generating PLG nanoparticles for controlled anti-cancer drug delivery. Pharm. Res. 35, 59 (2018).